Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹1,792 Cr
Revenue (TTM)
₹1,758 Cr
Net Profit (TTM)
₹-114 Cr
ROE
-7.3 %
ROCE
-0.4 %
P/E Ratio
--
P/B Ratio
1.9
Industry P/E
33.39
EV/EBITDA
28
Div. Yield
0.1 %
Debt to Equity
1
Book Value
₹103
EPS
₹-11.7
Face value
2
Shares outstanding
92,303,605
CFO
₹1,263.74 Cr
EBITDA
₹1,817.81 Cr
Net Profit
₹630.52 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Indoco Remedies
| -18.2 | -5.2 | -19.3 | -16.9 | -15.8 | -7.4 | -3.5 |
|
BSE Healthcare
| -2.9 | -2.7 | -3.0 | 4.1 | 25.1 | 15.7 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Indoco Remedies
| -29.4 | -14.9 | -2.8 | -10.5 | 49.3 | 61.3 | -12.1 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Indoco Remedies
|
191.9 | 1,792.1 | 1,758.1 | -116.4 | -1.8 | -10.8 | -- | 1.9 |
| 348.0 | 3,112.8 | 2,521.8 | 202.5 | 9.6 | 14.3 | 15.4 | 2.1 | |
| 927.5 | 11,539.7 | 2,512.3 | 543.7 | 28.3 | 19.3 | 21.2 | 3.6 | |
| 372.0 | 6,657.6 | 1,053.1 | 293.6 | 32.3 | 24.6 | 22.7 | 5.1 | |
| 1,133.0 | 11,940.9 | 1,158.7 | 309.6 | 31.9 | 17.3 | 38.2 | 6.3 | |
| 1,505.5 | 29,049.9 | 8,850.1 | 894.8 | 15.2 | 19.8 | 33.4 | 5.8 | |
| 12,137.0 | 15,918.8 | 1,575.1 | 179.1 | 14.9 | 11.4 | 88.9 | 9.6 | |
| 1,858.0 | 3,162.1 | 673.7 | 202.6 | 17.6 | 19.4 | 15.6 | 5.5 | |
| 759.3 | 3,444.8 | 588.5 | 102.9 | 22.1 | 12.7 | 33.9 | 4.1 | |
| 135.4 | 3,636.7 | 7.1 | -274.7 | -4,008.3 | -140.4 | -- | 5.5 |
Indoco Remedies Limited manufactures, markets, and sells formulations and active pharmaceutical ingredients in India and internationally. It offers stomatological, gastrointestinal, respiratory, anti-infective, vitamin/mineral/nutrient,... ophthal/ontological, antifungal, hormonal, dermatology, urological, anti-diabetic, gynaecological, lifestyle management, pain/analgesic, and cardiac products. The company also provides branded generics comprising analgesic tablets and topical preparations; anti-hypertensive; protein supplements; multivitamin tablets and syrups; antibiotic tablets, syrups, and injectables; oral rehydration powders; anti-haemorrhoidals; antacids; antihistaminic; etc. In addition, it provides analytical services, such as impurity profile, particle size analysis, polymorphism and compatibility studies, heavy metal analysis, extractables and leachables studies, lyophilization studies, reference and working standards, forced degradation studies, and chromatographic method development and validation services. Further, the company offers architectural design, lighting, mechanical and utility engineering, project and construction management, electrical, control system, piping, structural design, data transfer system, and process engineering. Additionally, it provides contract research services, such as custom synthesis of molecules and intermediates, process chemistry research and development, non-infringing process designing and scale up, and analytical method development/validation solutions, as well as contract manufacturing services. The company was formerly known as Indo Continental Trading Company. Indoco Remedies Limited was founded in 1945 and is based in Mumbai, India. Read more
Incorporated
1947
Chairman
Suresh G Kare
Managing Director
Aditi Panandikar
Headquarters
Mumbai, Maharashtra
Website
Looking for more details about Indoco Remedies Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The share price of Indoco Remedies Ltd is ₹191.90 (NSE) and ₹193.45 (BSE) as of 19-Mar-2026 10:24 IST. Indoco Remedies Ltd has given a return of -15.82% in the last 3 years.
Since, TTM earnings of Indoco Remedies Ltd is negative, P/E ratio is not available.
The P/B ratio of Indoco Remedies Ltd is 1.89 times as on 18-Mar-2026, a 13 discount to its peers’ median range of 2.16 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
2.12
|
|
2024
|
30.76
|
2.74
|
|
2023
|
21.09
|
2.92
|
|
2022
|
22.42
|
3.84
|
|
2021
|
28.57
|
3.46
|
The 52-week high and low of Indoco Remedies Ltd are Rs 349.80 and Rs 187.73 as of 19-Mar-2026.
Indoco Remedies Ltd has a market capitalisation of ₹ 1,792 Cr as on 18-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Indoco Remedies Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹-1.69
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.